Atara Biotherapeutics announced that it has entered into a definitive agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727 shares of its common stock at a purchase price of $0.55 per pre-funded warrant share in a registered direct offering to entities affiliated with an existing institutional investor. The pre-funded warrants will have an exercise price of $0.0001 per share, and will be immediately exercisable upon issuance. The offering is expected to close on or about January 10, 2024, subject to the satisfaction of customary closing conditions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ATRA:
- Atara Biotherapeutics presents ‘positive’ preclinical data on ATA3431 at ASH
- Atara Biotherapeutics to present ‘positive’ tab-cel data during ESMO session
- Atara Biotherapeutics price target lowered to 40c from $1.40 at Citi
- Atara Biotherapeutics downgraded to In Line from Outperform at Evercore ISI
- Atara Biotherapeutics price target lowered to $13 from $19 at Canaccord
